Journal article
Jonathan C Markle, Jacqueline K. Shaia, Harman Araich, Neha Sharma, Katherine E. Talcott, Rishi P. Singh
JAMA ophthalmology, 2024
JAMA ophthalmology, 2024
Semantic Scholar
DOI
PubMed
Cite
Cite
APA
Click to copy
Markle, J. C., Shaia, J. K., Araich, H., Sharma, N., Talcott, K. E., & Singh, R. P. (2024). Longitudinal Trends and Disparities in Diabetic Retinopathy Within an Aggregate Health Care Network. JAMA Ophthalmology.
Chicago/Turabian
Click to copy
Markle, Jonathan C, Jacqueline K. Shaia, Harman Araich, Neha Sharma, Katherine E. Talcott, and Rishi P. Singh. “Longitudinal Trends and Disparities in Diabetic Retinopathy Within an Aggregate Health Care Network.” JAMA ophthalmology (2024).
MLA
Click to copy
Markle, Jonathan C., et al. “Longitudinal Trends and Disparities in Diabetic Retinopathy Within an Aggregate Health Care Network.” JAMA Ophthalmology, 2024.
BibTeX Click to copy
@article{jonathan2024a,
title = {Longitudinal Trends and Disparities in Diabetic Retinopathy Within an Aggregate Health Care Network.},
year = {2024},
journal = {JAMA ophthalmology},
author = {Markle, Jonathan C and Shaia, Jacqueline K. and Araich, Harman and Sharma, Neha and Talcott, Katherine E. and Singh, Rishi P.}
}
Abstract
Importance Diabetic retinopathy (DR) is a leading cause of blindness in the US, warranting updates on its prevalence and incidence in the setting of advancements in diabetic care over recent years.
Objective To determine recent trends in DR prevalence stratified by baseline demographics to identify those populations at greater risk.
Design, Setting, and Participants This was a cross-sectional epidemiologic evaluation conducted using deidentified data from the large federated TriNetX Analytics health research network composed of 56 health care organizations in the US. Patients from 2015 to 2022 who had an International Statistical Classification of Diseases and Related Health Problems, Tenth Revision code of type 1 DR (T1DR) or type 2 DR (T2DR) were included in this analysis. Patients were further stratified by age cohorts (20-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, and 70 years or older), race and ethnicity, and sex.
Main Outcomes and Measures Prevalence per 100 000 patients and prevalence odds ratios (ORs) were calculated in Microsoft Excel and Posit (formerly RStudio).
Results A total of 359 126 patients with T1DR or T2DR (mean [SD] age, 67 [14] years; 52% female) were included in this study between January 1, 2015, and December 21, 2022. T1DR increased in prevalence from 2015 to 2022, with T1DR increasing 1.15-fold affecting 70.4 patients per 100 000 in 2022. T2DR increased 1.07-fold affecting 461.7 patients per 100 000 in 2022. For T1DR, the cohort aged 20 to 39 years had the most substantial increase at 4.7 and 1.96 fold. Overall, White males had the largest prevalence ORs of T1DR at 1.41 (95% CI, 1.36-1.47) compared with White females (reference group). In T2DR, patients aged 20 to 39 years again had a 2.5- and 1.6-fold prevalence increase from 2015 to 2022. Regardless of age group, Hispanic males demonstrated larger prevalence OR at 4.08 (95% CI, 3.97-4.19) compared with White females followed by Hispanic females at 2.49 (95% CI, 2.42-2.56), Black males at 2.23 (95% CI, 2.17-2.29), and Black females at 2.00 (95% CI, 1.95-2.05).
Conclusion and Relevance The prevalence of both T1DR and T2DR increased in this network from 2015 to 2022, with individuals aged 20 to 39 years showing large increases. Additionally, T2DR was associated with greater increases in both Hispanic and Black communities. These findings support DR screening in young adults and for T2DR interventions specifically designed for racial and ethnic minoritized patients most affected by disease. Future investigations are warranted to further investigate these trends among young adults.